- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06340334
Efficacy and Safety of Tegoprazan Dual Therapy and Furazolidone-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a prospective, multicenter, open-label, randomized, parallel-controlled study. A total of 600 Hp-positive patients who had not received Hp eradication therapy before or who had previously eradicated Hp but had not undergone eradication therapy in the past six months were recruited, and the basic clinical data of the patients (age, gender, drug allergy history, diagnosis and treatment, etc.) were recorded, and they were randomly divided into two groups according to the ratio of 1:1. Group A subjects received oral Tegoprazan 50mg, bid + amoxicillin 1000mg, tid; Group B subjects received oral Tegoprazan 50 mg, bid + amoxicillin 1000 mg, bid + furazolidone 100 mg, bid + colloidal pectin bismuth 300 mg, bid. The duration of treatment is 14 days.
During the 14-day eradication treatment period, all participants were asked to record their adverse reactions and adherence to the medication. On the 7th and 14th days of medication, the researchers will conduct follow-up visits through WeChat or telephone to determine the adverse reactions and compliance of the patients, and observe and record whether the subjects have nausea, diarrhea, dizziness, bitter mouth, rash, constipation and other adverse reactions. In addition, subjects returned to the hospital 4-6 weeks after the end of treatment to check for H. pylori eradication by 13C-UBT or 14C-UBT.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18-65 years old;
- Patients who have had a positive 13C or 14C breath test and have not received Helicobacter pylori eradication therapy before, or who have failed to eradicate in the early stage but have not received eradication therapy within half a year;
- Voluntarily join this trial and sign the informed consent form.
Exclusion Criteria:
- Allergy to the study drug (penicillin, amoxicillin, furazolidone, Tegoprazan, etc.);
- Patients with active peptic ulcer disease;
- Patients who have received Helicobacter pylori eradication therapy within half a year;
- Use of antibiotics, bismuth, histamine H2 receptor antagonists or PPIs for 4 weeks before starting study treatment;
- use of adrenocorticosteroids, non-steroidal anti-inflammatory drugs or anticoagulants;
- History of esophageal or gastric surgery;
- Pregnant or lactating women;
- Suffering from serious concomitant diseases, such as liver disease, cardiovascular disease, lung disease, kidney disease;
- Alcoholism.
- Gastric mucosa-associated lymphoid tissue lymphoma (MALT), malignant tumor diseases.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A
oral Tegoprazan 50 mg, bid+amoxicillin 1000 mg, tid.
The duration of treatment is 14 days.
|
A total of 600 Hp-positive patients who had not received Hp eradication therapy before or had had Hp eradication in the early stage but had not undergone eradication therapy in the past six months were randomly divided into two groups: group A subjects received Tegoprazan 50 mg, bid + amoxicillin 1000 mg, tid; Group B subjects received Tegoprazan 50 mg, bid + amoxicillin 1000 mg, bid + furazolidone 100 mg, bid + colloidal pectin bismuth 300 mg, bid.
The duration of treatment is 14 days.
The eradication rate, adverse reactions, and compliance of the two groups were compared.
Other Names:
|
Active Comparator: Group B
oral Tegoprazan 50 mg, bid + amoxicillin 1000 mg, bid + furazolidone 100 mg, bid + colloidal pectin bismuth 300 mg, bid.
The duration of treatment is 14 days.
|
A total of 600 Hp-positive patients who had not received Hp eradication therapy before or had had Hp eradication in the early stage but had not undergone eradication therapy in the past six months were randomly divided into two groups: group A subjects received Tegoprazan 50 mg, bid + amoxicillin 1000 mg, tid; Group B subjects received Tegoprazan 50 mg, bid + amoxicillin 1000 mg, bid + furazolidone 100 mg, bid + colloidal pectin bismuth 300 mg, bid.
The duration of treatment is 14 days.
The eradication rate, adverse reactions, and compliance of the two groups were compared.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Helicobacter pylori eradication rate
Time Frame: 4-6 weeks after the end of the last dose
|
The eradication effect of Helicobacter pylori was detected by 13C-UBT or 14C-UBT
|
4-6 weeks after the end of the last dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Security observations
Time Frame: Days 7 and 14 of eradication treatment
|
Adverse reactions such as nausea, diarrhea, dizziness, change in taste, rash, constipation, etc
|
Days 7 and 14 of eradication treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient compliance
Time Frame: Within 3 days after the end of treatment
|
Actual amount of medication taken as a proportion of the total amount of medication to be taken during the 14-day treatment period
|
Within 3 days after the end of treatment
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents, Local
- Anti-Infective Agents
- Enzyme Inhibitors
- Gastrointestinal Agents
- Anti-Bacterial Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Monoamine Oxidase Inhibitors
- Antacids
- Anti-Infective Agents, Urinary
- Antitrichomonal Agents
- Amoxicillin
- Bismuth
- Furazolidone
Other Study ID Numbers
- KY20240123-05
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Helicobacter Pylori Infection
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...RecruitingHelicobacter Pylori Infection | Helicobacter Pylori EradicationBangladesh
-
Shandong UniversityRecruitingHelicobacter Pylori Infection | Patient Education | Helicobacter Pylori EradicationChina
-
Shandong UniversityCompletedHelicobacter Pylori Infection Helicobacter Pylori Eradication Patient EducationChina
-
Shanghai Jiao Tong University School of MedicineCompletedCure Rate of Helicobacter Pylori InfectionChina
-
Seoul National University Bundang HospitalRecruitingHelicobacter Pylori Infection | Helicobacter Pylori 23S rRNA Clarithromycin Resistance Mutation | Helicobacter Pylori Associated Gastrointestinal Disease | Helicobacter Pylori Infection, Susceptibility toKorea, Republic of
-
The First Affiliated Hospital of Nanchang UniversityUnknownBacterial Infection Due to Helicobacter Pylori (H. Pylori) | Eradication Therapy of Helicobacter Pylori | Detection of Helicobacter PyloriChina
-
Tanta UniversityNot yet recruitingPersistent Helicobacter Pylori InfectionEgypt
-
Nanjing First Hospital, Nanjing Medical UniversityCompletedHelicobacter Pylori 23S rRNA/gyrA Gene Mutation Detection Kit (Fluorescence PCR Fusion Curve Method)Helicobacter Pylori Infection | Helicobacter Pylori gyrA Levofloxacin Resistance Mutation | Fecal Drug Resistance Gene Detection | Helicobacter Pylori Infection, Susceptibility toChina
-
Kaohsiung Veterans General Hospital.Kaohsiung Medical University Chung-Ho Memorial HospitalCompletedHelicobacter Pylori InfectionTaiwan
-
National Taiwan University HospitalCompleted
Clinical Trials on Tegoprazan-amoxicillin dual therapy
-
Shandong UniversityNot yet recruitingHelicobacter Pylori InfectionChina
-
HK inno.N CorporationCompletedHelicobacter Pylori InfectionKorea, Republic of
-
National Taiwan University HospitalMinistry of Science and Technology, TaiwanRecruitingHelicobacter Pylori InfectionTaiwan
-
University of British ColumbiaUniversité de MontréalUnknown
-
University of EdinburghBritish Heart FoundationCompletedCoronary Artery Disease | Acute Coronary SyndromeUnited Kingdom
-
Hospital da Senhora da OliveiraRecruitingGastritis | Gastric Cancer | Helicobacter Pylori InfectionPortugal
-
Qilu Hospital of Shandong UniversityNot yet recruitingAcute Coronary Syndrome | Helicobacter Pylori InfectionChina
-
Shandong UniversityThe First Affiliated Hospital of Zhengzhou University; Zibo Central Hospital; Peking University Care Luzhong Hospital and other collaboratorsNot yet recruitingHelicobacter Pylori InfectionChina
-
Chengdu University of Traditional Chinese MedicineCompletedFailure After Assisted Reproductive TechnologyChina
-
Chengdu University of Traditional Chinese MedicineCompletedFailure After Assisted Reproductive TechnologyChina